Clinical Trial Update: Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase I trial evaluating the safety and immunogenicity of a recombinant Tat protein–based vaccine for HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tat protein-based HIV vaccine (recombinant Tat protein vaccine)

Snippet

Sponsor: Istituto Superiore di Sanità | Conditions: HIV Infections | Phase 1 | Status: COMPLETED